Target-specific monoclonal antibodies detect the GPCRs PAR1 or DRD2 expressed on live cell surfaces by Flow Cytometry

G protein-coupled receptors (GPCRs) are the largest family of multi-transmembrane proteins, and major targets for drug discovery. Antibody staining/detection of GPCR targets on live cells is important for studying receptor expression, localization, and dynamics in their native, functional state. Due to their complex structure and dynamic conformations, it is very challenging to develop antibodies against GPCRs. Protease-activated receptor-1 (PAR1) and Dopamine receptor D2 (DRD2) are Class A GPCRs. PAR1 is a promising target for cancer therapeutics, while DRD2 is a pivotal target for therapeutic intervention in the treatment of neuropsychiatric disorders.